Actualización en cáncer de páncreas y de vías biliares

  1. Gordo, A.M. Jiménez
  2. Gómez, M. López
  3. Casado, E.
  4. Molina, R.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2017

Título del ejemplar: Enfermedades oncológicas (II) Tumores digestivos

Serie: 12

Número: 32

Páginas: 1919-1928

Tipo: Artículo

DOI: 10.1016/J.MED.2017.04.013 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Resumen Introducción Se trata de un grupo de enfermedades con mal pronóstico que con frecuencia se presentan con ictericia y síndrome constitucional. Cáncer de páncreas Se caracteriza por tener alta quimiorresistencia. Produce frecuentes recaídas locales y diseminación a distancia. El único tratamiento curativo es quirúrgico. Se recomienda la administración de quimioterapia adyuvante. En estadios avanzados la quimioterapia sistémica puede aumentar la supervivencia. Cáncer de vías biliares Los tumores de las vías biliares se pueden presentar intrahepáticos, extrahepáticos, en vesícula biliar y en ampolla de Vater. Cada uno tiene diferentes características biológicas y moleculares. El tratamiento de elección es la resección quirúrgica. Frecuentemente está indicada la quimioterapia y la radioterapia adyuvante o con intención radical en casos no resecables. En los pacientes con enfermedad diseminada se recomienda la administración de quimioterapia sistémica. Es muy importante en todos los casos el tratamiento sintomático e individualizar el tratamiento más adecuado para cada paciente de acuerdo con las características de la enfermedad y de la edad, estado general y comorbilidad.

Referencias bibliográficas

  • García Alfonso P, Martínez Marín V, Muñoz Martin AJ. Cáncer de páncreas. Oncología clínica. Volumen 2. Madrid: Editorial Panamericana; 2010. p. 197-212.
  • Chari ST, Leibson CL, Rabe KG, Ramson J, de Andrade M, Petersen GMl. Probability of pancreatic cáncer following diabetes: a population based study. Gastroenterology. 2005;129: 504-11.
  • Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. Antidiabetic medications and risk of pancreatic cáncer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:510-9.
  • Canto MI. Familial risk factors for pancreatic cáncer and screeening of high risk patients. UpToDate 2016.
  • Fernández del Castillo C. Clinical manifestations, diagnosis and staging of exocrine pancreatic cáncer. UptoDate 2016.
  • Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT. PET/CT fusión scan enchances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol. 2008;15:2465-71.
  • Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H. Postresection Ca 19.9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26:5918-22.
  • Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H. Serum carbohydrate antigen Ca 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cáncer. HPB (Oxford). 2014;16(5):430-8.
  • Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A. Potentially curable pancreatic cáncer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(21):2541-56.
  • Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H. A randomized trial of chemoradiotherapy and che-motherapy after resection of pancreatic cáncer. N Eng J Med. 2004;350:1200.
  • Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K. Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cáncer:a randomized controlled trial. JAMA. 2007;297:267-77.
  • Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D. Adjuvant chemotherapy with fluoruracil pplus folinic acid vs gemcitabine following pancreatic resection: a randomized controlled trial. JAMA. 2010;304:1073.
  • Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cáncer: a phase 3, open label randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248-57.
  • Neoptolemos JP, Palmer D, Ghaneh P, Valle JW, Cunningham D, Wadsley J. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine and capecitabine versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Abstr LBA4006. Citado en: J Clin Oncol 34, 2016 (suppl; abstr LBA4006).
  • Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP. Adjuvant treatments for resected pancreatic adenocarcinoma: a sys-tematic review and network meta-analysis. Lancet Oncol. 2013;14:1095-103.
  • Ryan DP, Mamon H. Initial chemotherapy and radiation for nonmetastatic locally advanced unresectable and borderline resectable exocrine pancreatic cáncer. UptoDate 2016.
  • Hammel P, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artru P. Effect of chemoradiotherapy versus chemotherapy on survival in patients with locally advanced pancreatic cáncer controlled after 4 months of gemcitabine with or without Erlotinib. The LAP07 Randomized Clinical Trial. JAMA. 2016;315:1844.
  • Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA. FOLFIRINOX for locally advanced pancreatic cáncer: a systematic review and patient level meta-analysis. Lancet Oncol. 2016;17:801.
  • Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell El. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resec-table pancreatic cáncer. Ann Surg. 2015;261:12-7.
  • Balaban EP, Mangu PB, Khorana A, Shah MA, Mukherjee S, Crane CH. Locally advanced, unresectable pancreatic cáncer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2654-68.
  • Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cáncer. N Eng J Med. 2011;364:1817-25.
  • Von Hoff D, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M. Increased survival in pancreatic cáncer with nab Paclitaxel plus Gemcitabine. N Eng J Med. 2013;369:1691-703.
  • Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27 (23):3778-85.
  • Cunningham D, Chan I, Stocken DD, Valle JW, Smith D, Steward W. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cáncer. J Clin Oncol. 2009;27(33):5513-8.
  • Sohal DP, Mangu PB, Khorana A, Shah MA, Philip PA, O’Reilly EM. Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2784-96.
  • Benavides M, Anton A, Gallego J, Gómez MA, Jiménez-Gordo A, La Casta A. Biliary tract cancers: SEOM clinical guidelines. Clinical Transl Oncol. 2015;17(12): 982-7.
  • Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DMl. Biliary tract cancers. N Eng J Med. 1999;341:1368-78.
  • Sia D, Hoshida Y, Villanueva A, Roayale S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144:829-40.
  • Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y. 18-Fluorodeoxygluccose positron emission tomography influences management decisions in patientes with biliary cáncer. J Am Coll Surg. 2008;206:57.
  • AJCC Cancer Staging Manual. 7ª ed. New York: Springer, Inc.; 2010.
  • Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188-95.
  • Van der Gaag NA, Kloek JJ, de Bakker JK, Musters B, Geskus RB, Busch OR. Survival analysis and prognostic nomogram for patients undergoing resection of exrahepatic cholangiocarcinoma. Ann Oncol. 2012;23:2642-94.
  • Moreno Anton F, Sastre Vlera J, Díaz-Rubio E. Factores pronósticos en el cáncer de hígado y vía biliar. Factores pronósticos en oncología. 2ª ed. Madrid: McGrawHill Interamericana; 2005.
  • Anderson ChD, Stuart KE. Treatment of localized cholangiocarcinoma: Adjuvant and neoadjuvant therapy and prognosis. UpToDate 2016.
  • Friman S, Foss A, Isoniemi H, Olausson M, Höckerstedt K, Yamamoto S. Liver transplantation for cholangiocarcinoma: selection is essential for aceptable results. Scand J Gastroenterol. 2011;46:370-5.
  • Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihiliar colangiocarcinoma at 12 US centers. Gastroenterology. 2012;143:88-98.
  • Rosen CB, Heimbach JK, Gore GJ. Liver transplantion for cholangiocarcinoma. Transpl Int. 2010;23:692.
  • Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM. SWOG S0809: A phase II Intergroup Trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33:1-6.
  • NCCN Guidelines. Hepatobiliary cancers. Version 2.2016.
  • Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraceyas A. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cáncer. N Eng J Med. 2010;362:1273-81.
  • Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cáncer. Br J Cancer. 2006;95:848.
  • Riechelmann RP, Townsley CA, Chin SN, Ond GR, Knox JJ. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary tract cancer. Cancer. 2007;110:1307.
  • Lamarca A, Hubner RA, Ryder WD, Valle JW. Second line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;25:2328-38.
  • Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N. Multivariate prognostic factors analysis for second line chemotherapy in advanced biliary tract cancer. Br J Cancer. 2014;110: 2165-9.
  • Chang DK, Jamieson NB, Johns AL, Scarlett CJ, Pajic M, Chou A. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol. 2013;31:1348.
  • Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, Mc-Donald AC. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC 3 periampullary cancer randomized trial. JAMA. 2012;308:147.
  • Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006;66:514.
Fuente de los datos: Dialnet